• linkedin
  • Increase Font
  • Sharebar

    Valeant to acquire Obagi for $344M


    Valeant Pharmaceuticals is acquiring Obagi Medical Products for nearly $344 million, just months after acquiring Medicis Pharmaceutical for $2.6 billion.

    The definitive agreement would allow Valeant to acquire all outstanding common stock of Obagi for $19.75 per share in cash. The deal is expected to close in the first half of 2013, according to a news release.

    Obagi’s skincare line includes the brands Nu-Derm, ELASTIDerm and CLENZIDerm. It posted revenue of $120 million in 2012. Obagi’s board of directors has unanimously approved the transaction.

    In fall 2012, Valeant acquired Medicis for $44 per share in cash. Valeant projected the net revenue for combining dermatology and aesthetic businesses with Medicis would be about $1.7 billion. Medicis produces hyaluronic acid fillers Restylane and Perlane, Dysport (abobotulinumtoxinA) and Zyclara (imiquimod cream 3.75 percent).

    Valeant’s deal with Obagi is expected to yield cost synergies of about $40 million within the first six months of closing, the company stated.

    “The acquisition of Obagi will be a valuable supplement to Valeant’s current dermatology portfolio and will further build upon our growing aesthetics franchise,” J. Michael Pearson, Valeant CEO and chairman, said in a news release. “The addition of (Obagi) products will not only strengthen and diversify our dispensed portfolio, but also expand our market presence with dermatologists and plastic surgeons.”

    Derm Pulse
    Article image

    Brought to you by:


    Latest Tweets Follow